Oxypurinol is an active metabolite of allopurinol and is an inhibitor of xanthine oxidase. Cardiome Pharma developed oxipurinol for the treatment of allopurinol-intolerant hyperuricemia (gout) and for the treatment of congestive heart failure. It is known, that inhibition of xanthine oxidase can improve myocardial work efficiency by sensitizing cardiac muscle cells to calcium ions, which are a key determinant of cardiac muscle function. However, all these studied were discontinued.

Glidazamide is an antidiabetic drug. It is a hypoglycemic agent that is part of the second-generation sulfonamide urea derivatives.

Metoquizine is a muscarinic acetylcholine receptor antagonist that was used as anti-ulcerative. Information about the current use of this compound is not available.

Nifuraldezone is an antibacterial compound. It completely mimics the radiosensitizing effect of molecular oxygen in hypoxic mammalian cells in vitro at concentrations in tissue culture medium which showed no measurable acute toxicity.

11-Deoxycortisol (also known as cortodoxone) is the predominant deoxycorticosteroid and is the immediate precursor of cortisol, which is formed by the enzymatic action of 11beta-hydrozylase (P450). Deficiency of this enzyme causes congenital adrenal hyperplasia, which is characterized by hypertension. 11-deoxycortisol is measured as part of the Metyrapone Test. Metyrapone blocks the formation of cortisol, resulting in increased secretion of Adrenocorticotropic hormone (ACTH) and 11-deoxycortisol in normal individuals.

Nifurquinazol, a 5-nitrofuran derivative, is an antibacterial agent.

Dichlorodifluoromethane, also known as Freon 12, was used as a refrigerant and aerosol spray propellant. However, its production was banned, because of the destroy the ozone layer. Experiments on animal failed to show any carcinogenic effects of this compound.